Pacira Ends Production of DepoCyt

07:13 EDT 30 Jun 2017 | Genetic Engineering News

Pacira Pharmaceuticals has disclosed that it will end production of its lymphoma treatment DepoCyt ® (cytarabine liposome injection) due to undisclosed manufacturing problems. Pacira cited “persistent technical issues specific to the DepoCyt(e) manufacturing process” in a regulatory filing yesterday. The company said its decision did not affect any treatments that had already been distributed to customers or administered to patients. As a result of its decision, Pacira said, it will incur a $5 million charge against second-quarter earnings related to the end of DepoCyt production. Half of the charge relates to writing off assets, $2 million to lease costs less estimated potential sublease income, and the remaining $0.5 million, to employee severance and other exit costs. DepoCyt is a sustained-release liposomal formulation of the chemotherapeutic agent cytarabine that uses the company’s DepoFoam drug delivery technology. DepoFoam consists of microscopic spherical particles composed of a honeycomb-like structure ...

Original Article: Pacira Ends Production of DepoCyt


More From BioPortfolio on "Pacira Ends Production of DepoCyt"

Quick Search


Relevant Topic

Drug Delivery
<!--LGfEGNT2Lhm-->Drug delivery is the method or process of administering a pharmaceutical compound to achieve a therapeutic effect in humans or animals.  <!--LGfEGNT2Lhm-->Drug delivery technologies are <!--LGfEGNT2Lhm-->patent pr...